Neurovascular Market's Time Has Come: Stealthy Sequent Medical Unveils Strategy
This article was originally published in Start Up
Executive Summary
With foresight, good timing, or simply years of experience, the founders of Sequent Medical (who also founded MicroVention) are launching a new endovascular product in Europe just as large companies are signalling their interest in the space via acquisitions. For the treatment of cerebral aneurysms, Sequent has developed a novel device that combines the best attributes of embolization coils and flow diverters, its founders believe.
You may also be interested in...
Market & Industry Briefs
Brief summaries of recent medtech market and industry developments. This month we cover recent activity in the stroke market and results of START-UP's recent survey of medical device venture capitalists.
Where are They Now? Yesterday's Stroke Companies
In May 2000, START-UP profiled five medical device companies targeting stroke, in an article entitled "Making Progress in Stroke." We recently revisited Radiant Medical, Medivance, MicroVention, and two others to find out what went according to plan and what didn't In 2007, we have to say that there has in fact not been much progress, at least in acute ischemic stroke. Two companies dropped out, two remain active with promising programs--in clinical areas other than stroke, and one, which avoided ischemic stroke in the first place, enjoyed a nice exit.
Microvention Inc.
Microvention Inc., a three-year-old start-up, is developing minimally invasive devices for treating cerebral vascular conditions. Its is first focusing on developing a better devices for treating aneurysms. It has a hybrid device, combining coils with a sponge-like hydrogel material that fills the aneurysm, cutting it off from the blood vessel. This allows the blood vessel to heal and recover its full strength. The product is in pre-clinical trials.